Factors influencing patient's perception of long-term treatment with low-molecular-weight heparins for cancer-associated thrombosis: an updated analysis of TROPIQUE, a prospective observational study

被引:4
|
作者
Debourdeau, P. [1 ]
Arvers, P. [2 ]
Hij, A. [3 ,4 ,5 ]
Bennani, H. [6 ]
Desauw, C. [7 ]
Falvo, N. [8 ]
Ghiringhelli, F. [9 ]
Hamade, A. [10 ]
Vedrine, L. [11 ]
Farge, D. [3 ,4 ,5 ]
机构
[1] Inst St Catherine, Unite Soins Support, 250 Chemin Baigne Pieds CS 80005, F-84918 Avignon, France
[2] Univ Grenoble Alpes, Lab Interuniv Psychol, BP 47, F-38040 Grenoble 9, France
[3] Hop St Louis, AP HP, Unite Med Interne Malad Autoimmunes & Pathol Vasc, 1 Ave Claude Vellefawc, F-75010 Paris, France
[4] Univ Paris 07, Paris, France
[5] Grp Francophone Thrombose & Canc, Paris, France
[6] Hop Rene Huguenin, Inst Curie, 35 Rue Daily, F-92210 St Cloud, France
[7] Hop Claude Huriez, Serv Oncol, Rue Michel Polonowski, F-59037 Lille, France
[8] Hop Bocage, Serv Med Interne, 2 Blvd Marechal Lattre Tassigny, F-21000 Dijon, France
[9] Ctr Anti Cancereux Ctr GF Leclerc, 1 Rue Prof Mar, F-21000 Dijon, France
[10] Hop Emile Muller, Unite Pathol Vasc, 20 Rue Docteur Laennec, F-68070 Mulhouse 10, France
[11] Hop Amer Paris, Serv Doncol, 63 Blvd Victor Hugo, F-92200 Neuilly Sur Seine, France
关键词
LMWH; Acceptability; Cancer; Experience; Quality of life; Venous thromboembolism; VENOUS THROMBOEMBOLISM PROPHYLAXIS; CLINICAL-PRACTICE GUIDELINES; ANTICOAGULATION THERAPY; ATRIAL-FIBRILLATION; PALLIATIVE CARE; GUIDANCE; PREVENTION; ADHERENCE;
D O I
10.1007/s00520-019-04815-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Our objective was to compare patient's expectations to their experience and to identify factors predictive of patient's perception of long-term LMWH for the treatment of cancer-associated thrombosis (CAT). Methods Results from the validated Perception Anticoagulant Treatment Questionnaires (PACTQ) completed before inclusion (PACTQ1 for expectations) and at the end (PACTQ2 for convenience and satisfaction) of the 6-month TROPIQUE study were studied with principal component analysis. Possible predictive factors of improved perception of LMWH treatment were analyzed with the Kruskall-Wallis test. Results Among 409 included patients treated with LMWH, 269 PACT-Q1 and 139 PACT-Q2 were evaluable for treatment perception. Patients had high expectations (A1-A7 score of 26.7 +/- 3.5, max = 35). Treatment cost (A7 = 1.90 +/- 1.31) and concern about a mistake in anticoagulation (A5 = 1.93 +/- 1.12) had little importance while LMWH treatment was considered easy to use (A4 = 4.20 +/- 0.93). Six-month treatment with LMWH was associated with a high rate of convenience (B1-B11, C1-C2 = 55.1 +/- 8.38, max = 65) and a high satisfaction score (D1-D7 = 25.1 +/- 4.32, max = 35). Patients' confidence in treatment and perception of possible LMWH side effects were moderate while perception of autonomy and independence significantly improved at the end of the study compared to inclusion. PACT-Q2 satisfaction score was low in patients who experienced bleeding (PACT-Q2 24.1 +/- 3.3 vs. 25.1 +/- 4.3). LMWH twice daily tended to be found less convenient compared than once daily (53.3 +/- 7.2 vs. 55.0 +/- 8.3). Conclusion CAT patients had a good perception of the 6-month LMWH treatment when comparing expectations and experience. Using a quantitative scale validated in the general population for VTE and subcutaneous injection and including a large number of patients, bleeding complications and LMWH twice daily were associated with a nonsignificant trend towards a worsen perception.
引用
收藏
页码:287 / 293
页数:7
相关论文
共 33 条
  • [1] Factors influencing patient’s perception of long-term treatment with low-molecular-weight heparins for cancer-associated thrombosis: an updated analysis of TROPIQUE, a prospective observational study
    P. Debourdeau
    P. Arvers
    A. Hij
    H. Bennani
    C. Desauw
    N. Falvo
    F. Ghiringhelli
    A. Hamadé
    L. Vedrine
    D. Farge
    Supportive Care in Cancer, 2020, 28 : 287 - 293
  • [2] Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study
    Seaman, Siwan
    Nelson, Annmarie
    Noble, Imon
    PATIENT PREFERENCE AND ADHERENCE, 2014, 8 : 453 - 461
  • [3] Barriers to the long-term use of low-molecular weight heparins for treatment of cancer-associated thrombosis
    Wittkowsky, A. K.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (09) : 2090 - 2091
  • [4] Cancer-Associated Thrombosis: Not All Low-Molecular-Weight Heparins Are the Same, Focus on Tinzaparin, A Narrative Review
    Fioretti, Agnese Maria
    Leopizzi, Tiziana
    Puzzovivo, Agata
    Giotta, Francesco
    Lorusso, Vito
    Luzzi, Giovanni
    Oliva, Stefano
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2022, 2022
  • [5] Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis
    Wumaier, Kaidireyahan
    Li, Wenqian
    Chen, Naifei
    Cui, Jiuwei
    THROMBOSIS JOURNAL, 2021, 19 (01)
  • [6] Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice
    den Exter, Paul L.
    Hooijer, Jose
    van der Hulle, Tom
    van Oosten, Julien P.
    Dekkers, Olaf M.
    Klok, Frederikus A.
    Huisman, Menno V.
    THROMBOSIS AND HAEMOSTASIS, 2017, 117 (11) : 2163 - 2167
  • [7] Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study
    Noble, SIR
    Finlay, IG
    PALLIATIVE MEDICINE, 2005, 19 (03) : 197 - 201
  • [8] Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis
    Kaidireyahan Wumaier
    Wenqian Li
    Naifei Chen
    Jiuwei Cui
    Thrombosis Journal, 19
  • [9] Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: Updated systematic review and meta-analysis of randomized controlled trials
    Moik, Florian
    Posch, Florian
    Zielinski, Christoph
    Pabinger, Ingrid
    Ay, Cihan
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2020, 4 (04) : 550 - 561
  • [10] Comparative Efficacy of Oral Apixaban and Subcutaneous Low Molecular Weight Heparins in the Treatment of Cancer-Associated Thromboembolism: A Meta-Analysis
    Baloch, Maryam F.
    Adepoju, Adedimeji, V
    Falki, Vaibhavkumar
    Hajjaj, Mohsin
    Habet, Tatiana
    Habet, Karina
    Mahrosh, Amtul
    Kundu, Sumana
    Kataria, Janvi
    Mathew, Midhun
    Saka, Tugba
    Al-Tawil, Mohammed
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (08)